Oral Conditions and Salivary Analysis in HIV-uninfected Subjects Using Preexposure Prophylaxis

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2022 Apr 3

PMID 35368014

Authors

N Macedo

G Baggio

I Henn

J Santos

T Batista

S Ignacio

P Souza

L Azevedo-Alanis

Affiliations

Soon will be listed here.

Abstract

Background: New prevention strategies have been advocated to control the progression of HIV/AIDS, such as preexposure prophylaxis (PrEP). The aim of this study is to evaluate the potential changes in the oral and salivary conditions of HIV-uninfected subjects using PrEP.

Material And Methods: Subjects were evaluated before beginning the medication (T0), at the first follow-up (T1), and at the second follow-up (T2). Xerostomia, presence of untreated cavitated caries, oral hygiene habits, taste, gingival and plaque index, stimulated salivary flow rate (SSFR), and salivary concentrations of calcium, glucose, urea, and total proteins were evaluated. Data obtained were analyzed using statistical tests (p<0.05).

Results: Forty-seven participants (41 men; 6 women) were evaluated at T0. Thirty (28 men; 2 women) and 17 men were reassessed at T1 and T2, respectively. There was no difference between the SSFR and oral and salivary conditions between T0, T1, and T2 (p>0.05), except for the salivary calcium concentration, that increased at T2 compared to T1 (p=0.02). There was significant difference between taste and xerostomia at T1 (p=0.017), and the need to drink to swallow at T2 (p=0.015). There was significant correlation between the reported amount of saliva and taste (p=0.039, r=-0.378) at T1.

Conclusions: The prolonged use of PrEP seems to be associated with reports of dry mouth and worsening of taste, possibly associated with increased salivary calcium concentration.

Citing Articles

Zhong H, Wei F, Song Y, Chen H, Ni Z Front Public Health. 2023; 11:1133657.

PMID: 36992898 PMC: 10040810. DOI: 10.3389/fpubh.2023.1133657.

References

Masia M, Padilla S, Robledano C, Lopez N, Ramos J, Gutierrez F . Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2011; 28(3):242-6. DOI: 10.1089/AID.2011.0052. View

Diz Dios P, Scully C . Antiretroviral therapy: effects on orofacial health and health care. Oral Dis. 2013; 20(2):136-45. DOI: 10.1111/odi.12093. View

Loe H, SILNESS J . PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963; 21:533-51. DOI: 10.3109/00016356309011240. View

Agha-Hosseini F, Mirzaii-Dizgah I, Mirjalili N . Relationship of unstimulated saliva cortisol level with severity of oral dryness feeling in menopausal women. Aust Dent J. 2011; 56(2):171-4. DOI: 10.1111/j.1834-7819.2011.01320.x. View

Frydrych A . Dry mouth: Xerostomia and salivary gland hypofunction. Aust Fam Physician. 2016; 45(7):488-92. View

Schiffman S, Zervakis J, Heffron S, Heald A . Effect of protease inhibitors on the sense of taste. Nutrition. 1999; 15(10):767-72. DOI: 10.1016/s0899-9007(99)00152-5. View

Pushpass R, Daly B, Kelly C, Proctor G, Carpenter G . Altered Salivary Flow, Protein Composition, and Rheology Following Taste and TRP Stimulation in Older Adults. Front Physiol. 2019; 10:652. PMC: 6555201. DOI: 10.3389/fphys.2019.00652. View

Marins L, Torres T, Luz P, Moreira R, Leite I, Hoagland B . Factors associated with self-reported adherence to daily oral pre-exposure prophylaxis among men who have sex with man and transgender women: PrEP Brasil study. Int J STD AIDS. 2021; 32(13):1231-1241. DOI: 10.1177/09564624211031787. View

Raja J, Rai P, Khan M, Banu A, Bhuthaiah S . Evaluation of gustatory function in HIV-infected subjects with and without HAART. J Oral Pathol Med. 2012; 42(3):216-21. DOI: 10.1111/jop.12006. View

10.

Saes Busato I, Ignacio S, Brancher J, Gregio A, Machado M, Azevedo-Alanis L . Impact of xerostomia on the quality of life of adolescents with type 1 diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 108(3):376-82. DOI: 10.1016/j.tripleo.2009.05.005. View

11.

Baggio G, Macedo N, Merlin J, Anghebem M, Santos J, Ignacio S . Inflammatory cytologic alterations in the oral epithelium associated with HIV pre-exposure prophylaxis: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021; 131(5):534-539. DOI: 10.1016/j.oooo.2021.01.010. View

12.

Peacock M . Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010; 5 Suppl 1:S23-30. DOI: 10.2215/CJN.05910809. View

13.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

14.

Penteado C, Batista T, Chaiben C, Bonacin B, Ventura T, Dionizio A . Salivary protein candidates for biomarkers of oral disorders in alcohol and tobacco dependents. Oral Dis. 2020; 26(6):1200-1208. DOI: 10.1111/odi.13337. View

15.

Dube M, Park S, Ross H, Love T, Morris S, Lee H . Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota. Sci Rep. 2018; 8(1):15212. PMC: 6185988. DOI: 10.1038/s41598-018-33524-6. View

16.

Nickolas T, Yin M, Hong T, Mugwanya K, Branch A, Heffron R . Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. Open Forum Infect Dis. 2019; 6(10):ofz338. PMC: 6778426. DOI: 10.1093/ofid/ofz338. View

17.

Drak D, Barratt H, Templeton D, OConnor C, Gracey D . Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service. PLoS One. 2019; 14(1):e0210106. PMC: 6336260. DOI: 10.1371/journal.pone.0210106. View

18.

McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

19.

SILNESS J, Loe H . PERIODONTAL DISEASE IN PREGNANCY. II. CORRELATION BETWEEN ORAL HYGIENE AND PERIODONTAL CONDTION. Acta Odontol Scand. 1964; 22:121-35. DOI: 10.3109/00016356408993968. View

20.

Mitchell D, Israr M, Alam S, Dinello D, Kishel J, Jia R . HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium. HIV Med. 2014; 15(4):196-202. PMC: 3942794. DOI: 10.1111/hiv.12100. View